Pharmos Starts Phase III Dexanabinol Study.(Pharmos Corp.)(Brief Article)

Pharmos Corp. initiated a pivotal Phase III study in Europe with dexanabinol for the treatment of traumatic brain injury, a study designed to support a new drug application to the FDA. "We feel one study will be sufficient if the protocol meets the requirements," said Gad Riesenfeld, president and chief operating officer of Pharmos. "The study will start in Europe and will take place …